



WAVE Life Sciences to Present at the Jefferies 2016 Healthcare Conference

June 1, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 3:00 PM Eastern Time on Wednesday, June 8, 2016 in New York, NY.

A live webcast will also be available on the investor relations page of WAVE Life Sciences' (the Company) corporate website at <http://ir.wavelifesciences.com/phoenix.zhtml?c=254233&p=irol-calendar>. After the live webcast, the event will remain archived on the Company's website until September 8, 2016.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE's deep, diverse [pipeline](#) spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com and follow us on Twitter at [@WAVELifeSci](#) and [LinkedIn](#).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160601005129/en/>

Source: WAVE Life Sciences Ltd.

For WAVE Life Sciences Ltd.

Media Contact:

Feinstein Kean Healthcare
Jess Rowlands, 202-729-4089
jessica.rowlands@fkhealth.com

or

Investor Contact:

Westwicke Partners
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com